Formycon has recently announced its preliminary and unaudited financial results for the first half of 2022. Formycon CEO Dr. Stefan Glombitza expressed his high satisfaction with the performance in the first half of the year and the excellent progress in the various development projects. The publication of the final figures respectively the half-year report is scheduled for October 28, 2022. For further details please have a look at our press release.
We will keep you up to date!News Distributor Subscription
Global Quality Biosimilars
© Formycon AGLegal Notice Data Protection